Gene therapy is a burgeoning market within the pharmaceutical industry and is teeming with new opportunities. Transparency Market Research’s latest report titled ‘Gene Therapy Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019’ provides a comprehensive analysis of one of the most critical medical fields. The market analyses and estimates contained in this report are of special significance to pharmaceutical companies, educational institutes, marketing professionals, and entrepreneurs venturing into the gene therapy market.
Key highlights of this report include: market growth drivers and restraints, current trends and emerging opportunities, value chain analysis, estimates and forecasts of segment-wise growth, as well as a profiles of all leading players in the gene therapy market over the period of forecast. The report also leverages the Porter’s five forces model to analyze the future threats and bargaining power of stakeholders such as suppliers, consumers and manufacturers. Other macro and micro factors that are essential for the sustenance of existing market players are encompassed in this report.
Gene therapy entails the use of DNA in the capacity of a drug, for the prevention or treatment of diseases. This is one of the most defining developments in the pharmaceutical industry, and is expected to have far-reaching implications on life-threatening diseases in the future. Some diseases that can be potentially treated using gene therapy include: cancer, HIV, and cystic fibrosis. It is anticipated that the clinical trial and biotechnology industry will largely benefit from gene therapy in the long run. And, it is possible that gene therapy could provide a cure for diseases that are regarded as being incurable today.
Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1838
Currently, the concept of gene therapy is being validated by numerous pharmaceutical companies using clinical data, and there is a growing interest among venture capitalists to explore the commercial potential of gene therapy. However, the growth of the gene therapy market is largely dependent on the regulatory environment, and on approvals from industry bodies. Currently, most gene therapy products are still in the clinical trials phase II and phase III, of which a majority focuses on the treatment of cancer and cardiovascular diseases. The growing popularity of DNA vaccines has positively impacted the growth of this market, and there is a high possibility of gene therapy being practiced in clinics in the next few years, as encouraging results are emerging from the phase II/III trials.
This report profiles key players such as: AnGes MG, Transgene, Urigen Pharmaceuticals, GenVec, Vical, BioSante Pharmaceuticals, Oxford BioMedica, and Genzyme Corporation.